의약품 특허의 강제실시권 비교법적 고찰

다국어 초록 (Multilingual Abstract)

To implement the Korea-U.S. Free Trade Agreement, the Patent-Regulatory Approval Linkage System will be enforced from March 2015. This has driven a growing concern about the side effects of evergreening, such as the inflation of drug prices and the delayed release of generics. The active evergreening approaches of multinational pharmaceutical companies over major essential drugs have recently sparked controversy over patenting and the right to health. Article 31 of the TRIPs Agreement allows the use of the compulsory license; thus, its member countries can regulate their patents. However, it also stipulates that the original purpose of a patent should not be overlooked when restricting the patent and that the interest of a patentee and a third party should be reasonably controlled. The international discussion on the compulsory license system can be considered as a process of establishing the balance point between a patentee’s own interest and public interests, such as public health considerations.
On April 1, 2013, India’s Supreme Court gave its ruling on Glivec, which was considered as a confrontation between a patent and the right to health with regard to guaranteeing accessibility to essential drugs. The government’s policy on the compulsory license for pharmaceutical patents has to invest a particularly considerable effort to establish a balance between the human right to health, on the one hand, and patents, on the other hand. The South Korea’s government has promoted the policy enhancing patent applications. Thus, it appears to have some concerns about potential side effects that can occur with the compulsory license system regulating patents.
As the compulsory license for pharmaceutical patent has never been exercised in South Korea, the requisite to public interests tends to be strictly interpreted. On the other hand, there are more than 100 cases that accepted the compulsory license for the sake of monopoly regulation as they put emphasis on the right to health. With regard to the implementation of the compulsory license for pharmaceutical patents, an objective and reasonable standard needs to be set in detail for the protection of the right to health.
It is expected that a policy will be able to be enacted in South Korea, which puts more emphasis on the right to health than the pharmaceutical patents regarding the compulsory license that is guaranteed by both international and domestic laws.

참고문헌 (Reference)

1 특허청, "해외지식재산권 보호가이드북" 2006

2 박지현, "한미FTA 속의 TRIPs-Plus" 국제법학회논총 53 (2) : 85 ~ 108 , 2008

3 조재신, "한·미 FTA 관련 개정 특허법에 대한 고찰" 법학논총 32 (3) : 49 ~ 83 , 2012

4 정상조, "특허법 주해 Ⅰ" 박영사 , 2010

5 이익희, "특허발명의 강제실시제도 공중보건문제를 해결하기 위한 제도개선을 중심으로" 지식재산 21 , 2005

6 정상조, "특허발명의 강제실시" 서울대학교 법학 40 (1) , 1999

7 남희섭, "특허발명의 강제실시" 산업재산권학회 춘계학술대회 발표문 , 2005

8 신혜은, "특허권자와 복제약 사업자의 역지불합의에 관한 연구 - 관련 미국판례와 공정거래위원회의 개정 심사지침을 중심으로 -" 산업재산권 (36) : 39 ~ 80 , 2011

9 이윤주, "특허권과 개발도상국에서의 의약품에 대한 접근과의 조화를 위한 모색" 산업재산권 (24) : 189 ~ 234 , 2007

10 송영식, "지적소유권법(제2판)" 육법사 , 2013

11 특허청, "조문별 특허법해설" 2007

12 김일규, "인도 대법원의 글리벡 특허소송 최종 판결 및 인도 특허법의 WTO TRIPS 협정과의 합치성에 대한 고찰" 지식재산연구 9 (1) : 45 ~ 83 , 2014

13 김원준, "의료 관련 발명의 특허법적 보호와 쟁점" 법학논총 32 (2) : 73 ~ 108 , 2012

14 정차호, "신종플루 등 대유행 전염병에 대비하기 위한 강제실시 제도의 개선방안" 법학논총 29 (2) : 7 ~ 46 , 2009

15 정연덕, "신기술분야에서의 강제실시의 적용에 관한 연구" 2009

16 박성호, "생명권, 건강권, 그리고 특허권 - 글리벡 특허권에 대한 강제실시문제" Jurist 2002 , 2001

17 임호, "미국의 FTA 협정 중 의약품 특허제도에 관한 연구" 지식재산연구 2 (1) , 2007

18 특허청, "미국 제네릭 의약품 판례분석 보고서" 2012

19 유병선, "공공의 이익을 위한 특허발명의 강제실시-의약발명을 중심으로" 2005

20 남희섭, "공공의 이익을 위한 특허발명의 강제실시" 창작과 권리 30 , 2003

21 권미란, "건강권을 넘어선 재산권, 이에 맞서는 의약품 접근권 투쟁" 비판과 대안을 위한 사회복지학회 학술대회 발표논문집 , 2008

22 백종수, "강제실시제도와 공중보건문제 해결" 배재대학교 법무대학원 , 2007

23 吉藤幸朔, "特許法槪說(제13판)" 대광서림 , 2000

24 中山信弘, "新⋅注解 特許法(上卷)" 靑林書院 , 2011

25 특허청, "WTO TRIPs 협정 조문별 해설" 2004

26 Keith E. Maskus, "The WTO, Intellectual Property Rights and the Knowledge Economy, An Elgar Reference Collection" 2004

27 Sheldon Burnshtein, "Sublicense or Supply Agreement? Supreme Court of Canada Interpretation Benefits Generic Phamaceutical Industry" Food & Drug Law Journal 54 , 1999

28 최치호, "Soft IP의 글로벌 동향, Global IP Trend 2012" 2012

29 Gunars Gaikis, "Pharmaceutical Patents in Canada, An update on compulsory licensing" Patent World , 1992

30 Janice M. Mueller, "PATENT LAW" Wolters Kluwer , 2009

31 Press Office, "National STD/AIDS Program, Brazilian Ministry of Health, OFFICIALNOTE" 2001

32 "Interpretation Benefits Generic Pharmaceutical Industry" Food & Drug Law Journal 54 , 1999

33 Carlos M. Correa, "Intellectual Prorerty Rights, the WTO and Develoing Countries" Zed Books Third World Network , 2000

34 Lionel Bently, "Intellectual Property Law (3rd edition)" OXFORD , 2009

35 Sol Goldstein, "A study of compulsory Licensing" 1997